Cellosaurus MCAS (CVCL_3020)

Cell line name MCAS
Accession CVCL_3020
Resource Identification Initiative To cite this cell line use: MCAS (RRID:CVCL_3020)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Doubling time: 27 hours (PubMed=4056530).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Ovarian mucinous cystadenocarcinoma (NCIt: C4026)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_U210 (MCAS-3)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): JCRB; PubMed=25877200; TKG

Markers:
AmelogeninX
CSF1PO10,11
D13S3178,12
D16S53912
D18S5115
D21S1129,31
D3S135816,17
D5S81811,13
D7S8208,11
D8S117911,12
FGA18,21
Penta D10,12
Penta E16
TH016,8
TPOX8,11
vWA14,17
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=4056530
Kidera Y., Yoshimura T., Ohkuma Y., Iwasaka T., Sugimori H.
Establishment and characterization of a cell line derived from mucinous cystadenocarcinoma of human ovary.
Nippon Sanka Fujinka Gakkai Zasshi 37:1820-1824(1985)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=11330945; DOI=10.1006/gyno.2001.6132
Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., Sato A., Inazawa J.
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Gynecol. Oncol. 81:172-177(2001)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x
Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=22246397; DOI=10.3892/or.2012.1626
Sato N., Saga Y., Mizukami H., Wang D., Fujiwara H., Takei Y., Machida S., Ozawa K., Suzuki M.
Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
Oncol. Rep. 27:1336-1340(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126-2126(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections JCRB; JCRB0240
TKG; TKG 0662
Cell line databases/resources CCLE; MCAS_OVARY
CGH-DB; 343-2
CGH-DB; 9356-4
Cosmic-CLP; 1240171
GDSC; 1240171
LINCS_LDP; LCL-1493
Ontologies EFO; EFO_0006453
Biological sample resources BioSample; SAMN03472857
Gene expression databases GEO; GSM659382
GEO; GSM827228
GEO; GSM851924
GEO; GSM887290
GEO; GSM888365
Polymorphism and mutation databases Cosmic; 849612
Cosmic; 931362
Cosmic; 948290
Cosmic; 1707559
Cosmic; 2429301
Cosmic; 2582802